https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
Oral once-daily dual-release hydrocortisone (DR-HC) replacement therapy has demonstrated an improved metabolic profile compared to conventional 3-times-daily (TID-HC) therapy among patients with primary adrenal insufficiency. This effect might be related to a more physiological cortisol profile, but also to a modified pattern of cortisol metabolism. This work aimed to study cortisol metabolism during DR-HC and TID-HC. A randomized, 12-week, crossover study was conducted. DC-HC and same daily dose of TID-HC were administered
Like
Comment
Share
